Guizhi Fuling Capsules Supplemented to Western Medicine for Treating 40 Cases of Ectopic Pregnancy

YIN Feng-ling; YAN Chun-yin; SHEN Zong-ji; QIAN Jun-ru; WANG Wei-qi; TANG Xin

您当前的位置：

首页 >

文章列表页 >

Guizhi Fuling Capsules Supplemented to Western Medicine for Treating 40 Cases of Ectopic Pregnancy

更新时间：2024-01-04

- Guizhi Fuling Capsules Supplemented to Western Medicine for Treating 40 Cases of Ectopic Pregnancy
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 19, Issue 6, Pages: 317-319(2013)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC：
- Published：2013
- 稿件说明：
移动端阅览
YIN Feng-ling, YAN Chun-yin, SHEN Zong-ji, et al. Guizhi Fuling Capsules Supplemented to Western Medicine for Treating 40 Cases of Ectopic Pregnancy[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(6): 317-319.
DOI：

YIN Feng-ling, YAN Chun-yin, SHEN Zong-ji, et al. Guizhi Fuling Capsules Supplemented to Western Medicine for Treating 40 Cases of Ectopic Pregnancy[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(6): 317-319. DOI：

摘要

目的: 探讨桂枝茯苓胶囊辅助西药保守治疗异位妊娠的临床疗效。方法: 80例异位妊娠患者随机分为观察组和对照组各40例。对照组采用米非司酮25 mg/次

口服

1次/12 h

连用3 d

总量150 mg;甲氨蝶呤(MTX)50 mg·m-2

总量分两侧臀部深部im 1次。观察组加服桂枝茯苓胶囊

口服

9粒/次

2次/d。共4周。监测血人绒毛膜促性腺激素(β-HCG)水平及包块变化情况

记录β-HCG降至正常及包块消失所需时间。结果: 观察组保守成功35例(90.0%)优于对照组的29例(72.5%)(P<0.05);观察组血β-HCG平均恢复时间(14.5±7.7)d

少于对照组的(18.4±8.5)d(P<0.05);观察组3周内包块缩小32例

优于对照组的21例(P<0.05);观察组2周内临床症状消失34例

优于对照组的23例(P<0.05)。结论: 桂枝茯苓胶囊配合甲氨蝶呤和米非司酮保守治疗异位妊娠

提高了保守治疗成功率

且临床使用安全。

Abstract

Objective: To investigate the curative effect of Guizhi Fuling capsules (GFC) supplemented to western medicine for treating ectopic pregnancy. Method: Eighty cases of ectopic pregnancy patients were randomly divided into the observation group and the control group

40 cases in each group.Mifepristone was used in control group

25 mg orally bid for 3 days; and methotrexate (MTX) 50 mg·m-2

deep intramuscular injection on both sides of the buttocks

once daily.On the basis of the control group

the observation group were received GFC 9 capsules bid for 4 weeks.Serum β-HCG level and mass changes were monitored

the β-HCG returned to normal and mass disappearance time required were recorded. Result: The conservative success rate (90%

35 cases) in the observation group was better than that (72.5%

29 patients) in control group (P<0.05).The average recovery time of serum β-HCG 35 of observation group was (14.5±7.7)d

less than that in control group (18.4±8.5)d (P<0.05).The mass narrowing of 32 cases in observation group in 3 weeks was better than that (21 cases) in control group.The clinical symptoms disappeared in 34 cases in observation group within 2 weeks was superior than 23 cases in control group (P<0.05). Conclusion: GFC combined with methotrexate and mifepristone improves the success rate of conservative treatment of ectopic pregnancy

and safe for clinical use.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Conservative Treatment for Ectopic Pregnancy of 48 cases by Combination of Chinese Traditional and Western Medicine

Experimental Study of Gongning Granule on Uterus Haemorrhage Induced by Drug-abortion

Determination of Methotrexate Level in Plasma Using Higher Doses Methotrexate by HPLC

Determinate Concentration of Methotrexate in Acute Lymphoblasticleukemia Children by HPLC

Clinical Effect of Danbie Capsule Combined with Mifepristone in Treatment of Uterine Fibroids

Related Author

LU Yan-feng

LI Chun-ying

LIANG Ai-hua

WANG Jin-hua

XUE Bao-yun

KUANG Xia

FENG Ling-ling

XIE Jun-ping

Related Institution

The First Hospital of Kaifeng

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰